Home healthcare provider Addus HomeCare (NASDAQ:ADUS) will be reporting earnings tomorrow after market hours. Here’s what to look for.
Addus HomeCare met analysts’ revenue expectations last quarter, reporting revenues of $289.8 million, up 7% year on year. It was a slower quarter for the company, with a slight miss of analysts’ sales volume estimates.
Is Addus HomeCare a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Addus HomeCare’s revenue to grow 4.7% year on year to $289.4 million, slowing from the 11.9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.36 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Addus HomeCare has missed Wall Street’s revenue estimates four times over the last two years.
Looking at Addus HomeCare’s peers in the healthcare providers & services segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Brookdale delivered year-on-year revenue growth of 3.5%, meeting analysts’ expectations, and Pediatrix Medical Group reported revenues up 1.2%, topping estimates by 3.6%. Brookdale traded up 2.5% following the results while Pediatrix Medical Group was also up 10.4%.
Read our full analysis of Brookdale’s results here and Pediatrix Medical Group’s results here.
Stocks generally had a good 2024. The Fed fought high inflation and won without sending the economy into a recession, otherwise lovingly known as a soft landing. The US Central Bank is now cutting rates. That, plus the election of Donald Trump in November 2024, sent markets even higher, and while some of the healthcare providers & services stocks have shown solid performance, the group has generally underpeformed, with share prices down 5.7% on average over the last month. Addus HomeCare is down 17.8% during the same time and is heading into earnings with an average analyst price target of $139 (compared to the current share price of $109.23).
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
